Astellas Pharma

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, established on April 1, 2005, through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Headquartered in Chuo-Ku, Tokyo, Astellas operates globally, with a strong presence in the Americas, Europe, Asia, and Oceania. The company specializes in the research, development, manufacture, and commercialization of pharmaceutical products. Astellas offers treatments across various therapeutic areas, including urological diseases, cancer, nephrology, infectious diseases, metabolic diseases, immunodeficiency, and transplantation. Notable global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. Astellas also has an active pipeline of drug candidates targeting conditions such as urothelial cancer and acute myeloid leukemia. With around 17,000 employees, Astellas is listed on the Tokyo Stock Exchange and is part of the Nikkei 225 index.